Moderate coffee and caffeine intake linked to lower cardiovascular risk overall, but experts flag energy drinks and unfiltered coffee as areas of concern
The American Heart Association has published its first dedicated scientific statement on caffeine and cardiovascular disease, synthesizing decades of observational and randomized trial data into a single evidence-based resource for clinicians and patients. The statement, led by Dr. Gregory M. Marcus of the University of California, San Francisco, and Dr. Frank B. Hu of the Harvard T.H. Chan School of Public Health, appears in Circulation on behalf of the AHA's Council on Lifestyle and Cardiometabolic Health, Council on Clinical Cardiology, and Stroke Council.
Moderate intake looks safe and potentially protective. Caffeine consumption up to roughly 400 mg per day, or about 3 to 5 cups of coffee, appears safe for most adults and is associated with lower risk of coronary heart disease, stroke, heart failure, atrial fibrillation, hypertension, and type 2 diabetes.
Atrial fibrillation risk may actually go down. Randomized trial evidence, including a trial abstaining coffee drinkers from caffeine versus continuing their habit, found that regular caffeinated coffee consumption reduced the risk of recurrent atrial fibrillation rather than increasing it, a finding that runs counter to long-standing clinical assumptions.
But PVCs tick up. While atrial fibrillation risk decreases, randomized data show caffeine consumption increases the frequency of premature ventricular contractions, illustrating how caffeine's effects vary by arrhythmia type.
The coffee-vs-caffeine distinction matters. Much of the protective signal comes from studies of coffee as a beverage rather than caffeine in isolation. Similar benefits have been observed with decaffeinated coffee, suggesting other bioactive compounds in coffee, such as chlorogenic acid and polyphenols, may drive some cardiometabolic benefits independent of caffeine itself.
Brewing method affects cholesterol. Unfiltered coffee (French press, Turkish, Scandinavian boiled) raises LDL cholesterol due to a compound called cafestol, which is largely removed by paper filtering. Caffeine itself does not raise LDL.
Energy drinks are a different story. Data on high-dose caffeine, such as that found in energy drinks and shots, are more limited but consistently point toward cardiovascular harm, including case reports of dangerous arrhythmias and sudden cardiac events after high-dose caffeine consumption.
The relationship with blood pressure is complex. Acute caffeine intake can transiently raise blood pressure, but long-term habitual consumption shows an inverse J-shaped pattern, with minimal lasting effect at moderate intake levels.
Caffeine is among the most widely consumed psychoactive substances in the world, yet most of the research base is observational, and coffee's many non-caffeine compounds have historically made it difficult to isolate caffeine's specific cardiovascular effects. The new statement notes a growing body of randomized controlled trial data — including crossover and pragmatic trial designs — that is beginning to provide more definitive answers, particularly around atrial fibrillation.
The authors emphasize that genetic variation in caffeine metabolism (largely governed by the liver enzyme CYP1A2) helps explain why individuals respond so differently to caffeine, though there is not yet enough evidence to show these genetic differences meaningfully alter the long-term cardiovascular effects of habitual coffee consumption.
For most adults, the statement supports continued moderate coffee or caffeine consumption as compatible with a heart-healthy lifestyle. Clinicians are encouraged to consider brewing method (filtered vs. unfiltered) when counseling patients on cholesterol, to avoid blanket recommendations against caffeine for atrial fibrillation patients, and to counsel caution around energy drinks and high-dose synthetic caffeine products, where evidence points toward harm rather than benefit.
The writing group also cautions against extrapolating benefits seen with naturally occurring caffeine sources to synthetic or high-dose products, and flags "healthy user bias" , the tendency for people who moderately consume substances like coffee to also engage in other health-protective behaviors, as a persistent limitation across the observational literature.
